VeriLuce Therapeutics is an R&D/early-stage drug development company currently developing novel small molecules targeting concomitantly two chemokine receptors in dual antagonistic mode. The objective is to target such receptors within the tumour microenvironment to modulate the immune system to activate tumour-killing immune cells and suppress tumour-enhancing immune cells. Potential target indications for treatment include Triple Negative Breast cancer and Hepatocellular Carcinoma.

Event details

Date: June 3 - 6, 2024

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


42 in total